Latest news about Indrayani Biotech
Indrayani Biotech
11.50
+0.21(+1.86%)
Company Performance:
View Company Insights1D+1.86%
1M+1.68%
6M-25.03%
1Y-35.50%
5Y+14.66%
More news about Indrayani Biotech
10Apr 26
Indrayani Biotech Sets April 28 Record Date for ₹49.90 Crore Rights Issue
Indrayani Biotech Limited has finalized April 28, 2026 as the record date for its ₹49.90 crore rights issue following the Rights Issue Committee meeting on April 09, 2026. The issue comprises 3,25,25,897 partly paid-up equity shares priced at ₹15 per share with a 5:7 entitlement ratio, scheduled to open on May 27, 2026 and close on June 25, 2026.
10Apr 26
Indrayani Biotech Board Approves Food Division Demerger Evaluation and Committee Formation
Indrayani Biotech Limited's board meeting on April 9, 2026, resulted in approval for evaluating the demerger of its food division into a separate company and formation of a restructuring committee with full authority to manage the process. The board also appointed M/S VAITHIANATHAN & ASSOCIATES as internal auditor for two financial years (2025-26 and 2026-27).
09Apr 26
Indrayani Biotech Limited Clarifies Share Price Movement Following Rights Issue and Demerger Intimations
Indrayani Biotech Limited clarified to BSE that recent share price movement resulted from market reaction to two key intimations made on April 6, 2026. These included notification of a Rights Issue Committee meeting and Board Meeting scheduled for April 9, 2026, to discuss ongoing Rights Issue process and potential demerger of the food business respectively. The company confirmed no undisclosed material information exists and emphasized its commitment to regulatory compliance.
04Apr 26
Indrayani Biotech Limited Submits SEBI Compliance Certificate for Q4FY26
Indrayani Biotech Limited submitted its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 for Q4FY26 ended March 31, 2026. The certificate, issued by RTA MUFG Intime India Private Limited, confirms proper handling of dematerialized securities and adherence to prescribed timelines. The submission was made to both major depositories with copies to BSE Limited for listing compliance.
25Mar 26
Indrayani Biotech Board Formally Accepts Whole-time Director's Resignation
Indrayani Biotech Limited's Board of Directors formally accepted the resignation of Whole-time Director Mr. Singarababu Indirakumar during their meeting on March 24, 2026. The director had originally resigned on March 16, 2026, citing professional reasons, and the resignation became effective from the close of business hours on March 24, 2026. The Company has maintained full regulatory compliance under SEBI regulations throughout the transition process.
27Feb 26
Indrayani Biotech Reports Q3FY26 Results, Appoints New CFO and Resolves Compliance Issues
Indrayani Biotech announced Q3FY26 financial results showing mixed performance with standalone revenue declining 36.5% to ₹520.10 lakhs while consolidated revenue surged 102.2% to ₹3,501.48 lakhs. The company underwent leadership changes with the appointment of Mr. Kunisetty Venkateswara Rao as new CFO and secured strategic credit facilities worth ₹5 crores from Indus Finance Limited.
31Jan 26
Indrayani Biotech Limited Receives SARFAESI Notice from Hinduja Leyland Finance for NPA Classification
Indrayani Biotech Limited disclosed receiving a SARFAESI notice from Hinduja Leyland Finance Limited for NPA classification of term loans. The company has outstanding amounts of Rs. 6.46 crore as borrower and Rs. 19.12 crore as co-borrower, with current defaults of Rs. 47.56 lakh and Rs. 1.41 crore respectively. The company is evaluating the notice and plans to take necessary actions to regularize accounts and protect stakeholder interests.
19Dec 25
Indrayani Biotech Reports Q2FY26 Results with Mixed Performance and Board Changes
Indrayani Biotech reported mixed Q2FY26 performance with consolidated revenue growing 16.66% to ₹3,594.85 lakhs while net profit declined 25.04% to ₹91.21 lakhs. Standalone operations showed contrasting results with 37.60% revenue decline but 373.51% profit improvement. The company implemented board changes including director resignation and committee reconstitution.
20Sept 25
Indrayani Biotech Secures BSE In-Principle Approval for Rights Issue of Partly Paid-up Equity Shares
Indrayani Biotech Limited has received in-principle approval from BSE Limited for a proposed rights issue of partly paid-up equity shares. The approval, dated September 19, 2025, with reference number LOD/RIGHT/TT/FIP/920/2025-26, was announced through a regulatory filing signed by the company's Whole-time Director, Swaminathan G. The company officially informed BSE about the approval on September 20, 2025, under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Indrayani Biotech is listed on BSE with scrip code 526445.
16Sept 25
Indrayani Biotech's Subsidiary Secures SEBI Approval for Category II Alternative Investment Fund
Indrayani Biotech Limited's wholly-owned subsidiary, IBL Investments Limited, has received approval from SEBI for a Category II Alternative Investment Fund (AIF) registration. The fund, named IBL INVESTMENT TRUST, has been granted perpetual registration effective September 15, 2025, with the registration number IN/AIF2/25-26/1900. This approval allows IBL Investments Limited to operate as a SEBI-registered Category II AIF, enabling it to invest in various strategies including private equity, debt funds, and fund of funds.
15Aug 25
Indrayani Biotech Reports Mixed Q1 Results: Standalone Profit Steady, Consolidated Revenue Declines
Indrayani Biotech Limited (IBL) released Q1 financial results showing mixed performance. Standalone net profit slightly increased to ₹12.77 crore, but revenue fell 38% to ₹668.57 crore. Consolidated results were more challenging, with revenue dropping 7.7% to ₹2,910.37 crore and net profit declining 81.6% to ₹15.65 crore. Standalone EPS remained stable at ₹0.03, while consolidated EPS decreased from ₹0.10 to ₹0.03. The company's board meeting was held on August 14, 2025, and statutory auditors provided an unmodified opinion on the results.
Industry Peers
LT Foods
KRBL
Gujarat Ambuja Exports
Kaveri Seed Company
Trualt Bioenergy
GRM Overseas
Sanstar
Chaman Lal Setia Exports
Gulshan Polyols
Avt Natural Products
384.85
(-0.13%)
356.65
(+1.60%)
155.86
(+0.57%)
858.40
(+0.06%)
505.15
(+0.43%)
152.18
(+0.32%)
117.96
(+2.79%)
278.85
(-0.71%)
201.64
(+7.38%)
69.16
(+0.09%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
